Illumina, Inc. (NASDAQ:ILMN) Receives $156.88 Average PT from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been given an average recommendation of “Hold” by the eighteen brokerages that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $156.8824.

ILMN has been the subject of several recent analyst reports. Leerink Partners raised their price objective on shares of Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Canaccord Genuity Group boosted their target price on shares of Illumina from $140.00 to $190.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. Wall Street Zen lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Royal Bank Of Canada initiated coverage on shares of Illumina in a report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target for the company. Finally, JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th.

Illumina Stock Up 5.3%

Shares of Illumina stock opened at $205.09 on Friday. The stock’s 50-day moving average is $175.49 and its 200 day moving average is $146.83. Illumina has a one year low of $88.00 and a one year high of $205.47. The firm has a market cap of $31.03 billion, a price-to-earnings ratio of 37.29, a PEG ratio of 2.88 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the company posted $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina will post 5.22 EPS for the current year.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company’s stock, valued at approximately $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at approximately $3,771,540. The trade was a 2.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,003,769 shares of company stock worth $155,710,908. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC grew its position in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new position in Illumina during the second quarter worth $621,000. CW Advisors LLC acquired a new position in Illumina during the second quarter worth $275,000. Marshall Wace LLP lifted its stake in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after buying an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC lifted its stake in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after buying an additional 1,748 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 beat expectations: Revenue rose approximately 9.4% year over year to $1.16 billion, exceeding the $1.13 billion consensus estimate. Non-GAAP diluted EPS was $1.31, above expectations of about $1.23, while GAAP diluted EPS reached $1.35. Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised
• Positive Sentiment: Improved operating performance: Gross profit increased 10.8% to $770 million, and operating profit rose 14.5% to $245 million. Illumina reported a 21.1% GAAP operating margin and a 22.5% non-GAAP operating margin, supporting the case for expanding profitability. Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026
• Positive Sentiment: FY 2026 outlook was favorable: Adjusted EPS guidance was set at $5.30-$5.40, above the roughly $5.23 analyst consensus. Revenue guidance of approximately $4.6 billion, with a midpoint near $4.62 billion, was also modestly ahead of expectations. Illumina Surprises With Q2 Sales and Outlook
• Positive Sentiment: Strategic validation: Eli Lilly joined Illumina’s Billion Cell Atlas alliance as a foundational participant, potentially strengthening Illumina’s position in genomic data and AI-driven drug discovery. Eli Lilly Joins Illumina’s Billion Cell Atlas
• Neutral Sentiment: Reported insider trading data showed substantially more selling than buying over the past six months, although the activity was not directly tied to the quarterly announcement and may have limited near-term relevance.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.